This page shows the latest atrial fibrillation news and features for those working in and with pharma, biotech and healthcare.
In both obstructive or non-obstructive HCM patients, physical exertion can cause fatigue or shortness of breath, and has also been associated with increased risks of atrial fibrillation, stroke, heart failure
In both obstructive or non-obstructive HCM patients, physical exertion can cause fatigue or shortness of breath, and has also been associated with increased risks of atrial fibrillation, stroke, heart failure
The FDA has approved Micro Labs and Mylan’s generics to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF), one of Eliquis’ key indications.
drug for atrial fibrillation, citing safety concerns. ... The treatment landscape is currently missing a rapid, efficacious and well tolerated option to treat patients with recent onset atrial fibrillation and we believe Brinavess has the potential to
Five patients experienced grade 3 or higher treatment-emergent adverse events, including lymphopenia, hypertension, anaemia, atrial fibrillation fatigue, febrile neutropenia, pain in extremity, septic shock and thrombocytopenia.
a role in detecting conditions such as atrial fibrillation, a deadly and often undiagnosed disease. ... partnered with pharma giant Johnson and Johnson to assess the impact of wearable technology on earlier detection of atrial fibrillation.
More from news
Approximately 10 fully matching, plus 118 partially matching documents found.
When Novel Oral Anticoagulants (NOACs) entered the market some years ago for the prevention of stroke in atrial fibrillation, the potential for market disruption was clear.
Accession is currently working with the NHS in the UK to prevent the devastating impact of stroke caused by atrial fibrillation (AF) through the use of digital technology.
Clinicians' ability to identify the correct patients for different stroke prevention treatments had been identified as a barrier to optimal management of non-valvular atrial fibrillation (NVAF).
XEN-D103 ion channel modulator for atrial fibrillation (phase I). 162.4. Anacor / Valeant.
American College of Cardiology (ACC) to educate cardiologists in China about stroke prevention in atrial fibrillation (AF) – a condition for which Boehringer markets Pradaxa (dabigatran).
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Prior to this, Beach held director-level roles at DBHC Consulting, the Atrial Fibrillation Association, and Just:: Health Communications.
Will lead commercialisation in Europe of atrial fibrillation treatment Brinavess. Jürgen Polifka has left his role at Merck and Co to join Canada-based biopharma Cardiome as general manager, sales and ... Polifka was most recently regional marketing
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Technology is another important enabler - as seen along the North West coast, where they are using portable ECG technology to screen for atrial fibrillation (AF) in an attempt to bring down
As the audit reveals, too many people with high risk conditions such as atrial fibrillation – a type of irregular heartbeat associated with the most serious strokes and heart attacks – are either
The Week After looks at the risks associated with atrial fibrillation - the teaser looks to capture the attention of cardiology to step in and act.
Improving the detection and management of high-risk conditions, such as high blood pressure, high cholesterol and Atrial Fibrillation (AF) that can cause CVD, as well as many cases of dementia,
enough for you, the National Institute for Health and Care Excellence (NICE) has approved the use of ‘AliveCor’, which is a mobile heart monitor that can detect, monitor, and manage atrial ... fibrillation – a potentially fatal irregular heart
More from PMHub
Approximately 1 fully matching, plus 8 partially matching documents found.
Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...